This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valstar Intravesical Solution
Endo International plc
Drug Names(s): valrubicin, valtaxin
Description: Valstar (valrubicin) is a semisynthetic analog of the anthracycline doxorubicin. It is a cytotoxic agent that affects a number of biological functions involving nucleic acid metabolism. After penetration into cells, it inhibits incorporation of nucleosides into nucleic acids, causes extensive chromosomal damage, and arrests cells in the G 2 phase of cell division. Although it does not bind strongly to DNA, its metabolites interfere with the normal DNA breaking-resealing action of DNA topoisomerase II.
Deal Structure: In April 2007, Indevus closed its acquisition of Valera which had been marketing the drug, Valstar, in the United States.
In January 2009, Endo Pharmaceuticals and Indevus Pharmaceuticals announced that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.
In February 2009, Endo Pharmaceuticals announced the completion of the tender offer by its wholly owned subsidiary, BTB Purchaser, for all of the outstanding shares of common stock of Indevus Pharmaceuticals. American Stock Transfer & Trust Company, the depositary for the tender offer, has advised Endo that, as of 5:00 p.m., New York City time, on February 20, 2009, the initial expiration of the...See full deal structure in Biomedtracker
Valstar Intravesical Solution News
Additional information available to subscribers only: